Vivendy Therapeutics is engaged in the development of enzyme replacement therapy.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Basel
State: Basel-Stadt
Zip:
Country: Switzerland
Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2007 | Series A | 3 | $15.4M |
BioMedPartners EQT life science TVM Capital BioMedPartners EQT life science TVM Capital |
6/2008 | Series B | 2 | $30.5M |
Aescap Venture TVM Capital Aescap Venture TVM Capital |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|